|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we review the current knowledge on the impairment of NKG2D-mediated cancer immunity through TGF-β and discuss therapeutic approaches aiming at counteracting this major immune escape pathway.
|
31803194 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on a thorough understanding of the NKG2D/NKG2DL system as well as of the most relevant escape strategies of tumors, the diligent and thoughtful design of novel treatment modalities harnessing the NKG2D/NKG2DL axis holds great promise for the future therapy of cancer.
|
30732494 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The immunomodulatory effects are consistent with a putative improvement in cancer immunosurveillance via the upregulation of the NKG2D receptor.
|
31234376 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we summarize the major findings regarding the antitumor immune response mediated by the NKG2D receptor and its ligands, and discuss the potential clinical applications of targeting the NKG2D/NKG2DL pathway for immunotherapy in cancer patients.
|
31720075 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The present study provides evidence that activation of LXR, by enhancing NKG2D ligand expression, can promote NK cell-mediated cytotoxicity and suggests a novel immune-mediated mechanism involving modulation of intracellular cholesterol levels in cancer cells.-Bilotta, M. T., Abruzzese, M. P., Molfetta, R., Scarno, G., Fionda, C., Zingoni, A., Soriani, A., Garofalo, T., Petrucci, M. T., Ricciardi, M. R., Paolini, R., Santoni, A., Cippitelli, M. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
|
31125275 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Studies have shown that CD4CD25Foxp3Treg cells suppress NKG2D expression on NK cells via a cell contact-dependent mechanism and increased TGF-β and IL-10 production in some cancer models.
|
31145286 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
|
30778749 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings demonstrated that NKG2D CAR-T cells targeted glioblastoma cells and cancer stem cells in an NKG2D-dependent manner, supporting the use of CAR-T therapy in glioblastoma therapeutic strategies.
|
31288857 |
2019 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
NKG2D ligands (NKG2DLs) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy.
|
29980239 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Immune recognition through NKG2D is implicated in cancer, atherosclerosis, transplant rejection, and inflammatory diseases, such as rheumatoid arthritis.
|
29279329 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Harnessing NKG2D pathway is considered a viable avenue in cancer immunotherapy over recent years.
|
29525346 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data provide a rationale to combine NKG2D-based immunotherapies with TMZ and IR.<i>Clin Cancer Res; 24(4); 882-95.©2017 AACR</i>.
|
29162646 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
This event made the glioblastoma cells a potent target for NK cell-mediated recognition through a NKG2D restricted mechanism. p53 siRNA-mediated knock-down and pharmacological inhibition (pifithrin-α), profoundly prevented the iPA action in restoring the immunogenicity of U343MG cells through a mechanism that is dependent upon p53 status of malignancy.
|
28884474 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
With a focus on the liver, here, we review current knowledge of NKG2D-mediated tumor surveillance and discuss evidence supporting a dual role for NKG2D in cancer immunity.
|
30150983 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Since the detection of ligands for NKG2D in sera of cancer patients is, in many human models, indicative of prognosis, a large number of studies have been undertaken to improve understanding of the biology regulating this receptor and its ligands, with the aim of translating this knowledge into clinical practice.
|
29521021 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, we demonstrated that the CS1-NKG2D biAb facilitated an enhanced immune synapse between CS1<sup>+</sup> MM cells and NKG2D<sup>+</sup> cytolytic innate and antigen-specific effector cells, which, in turn, activated these immune cells for improved clearance of MM.<i>Cancer </i>.
|
29769244 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
In this article, we review the recent developments of the fusion proteins with NKG2D/NKG2DL ligands in cancer immunotherapy.
|
29316666 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we review the post-transcriptional and post-translational mechanisms by which NKG2D ligands are modulated in cancer cells and their impact on patient prognosis.We discuss controversies and approaches to apply our understanding of the NKG2D ligand/NKG2D-axis for cancer therapy.
|
30254634 |
2018 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Real-time PCR was used to analyze NKG2D expression in paired cancer and adjacent non-malignant tissues in 139 gastric cancer patients between 2007 and 2010 in Shanghai Cancer Center.
|
28433635 |
2017 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> NKG2D ligands (NKG2DL) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy.
|
28659311 |
2017 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we show the robust potential of cytomegalovirus (CMV) vector expressing the NKG2D ligand RAE-1γ as CD8<sup>+</sup> T cell-based vaccine against malignant tumors.
|
28612942 |
2017 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our results define cancer cell NKG2D as an important regulator of tumor initiation in ovarian cancer and presumably other malignancies and thus challenge current efforts in immunotherapy aimed at enhancing NKG2D function.
|
28499126 |
2017 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
The specific examples of NKG2D and Erb-B are used that provide different characteristics and target profiles for CAR T-cell therapy of cancer.
|
28771104 |
2017 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings expose the need to selectively target the types of cancer that could benefit from NKG2D-based immunotherapy.
|
28128200 |
2017 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
The treatment of cancer through the induction of natural killer group 2, member D (NKG2D) ligands is of interest, but understanding of mechanisms controlling expression of individual ligand is limited.
|
28850101 |
2017 |